Bafna Pharmaceuticals Ltd

Bafna Pharmaceuticals Ltd

₹ 80.0 0.00%
22 Nov 3:40 p.m.
About

Incorporated in 1981, Bafna Pharmaceuticals
Ltd manufactures finished pharmaceutical formulations[1]

Key Points

Product Profile:[1][2][3]
Company is manufacturing over 336
licensed pharmaceutical formulations
and has globally registered 78 of its
products viz. Afenac-p Tab, Afenac-th
Tab, finished solid oral and liquid oral
dosage forms of Betalactam and Non – Betalactam and Cephalosporin products

  • Market Cap 189 Cr.
  • Current Price 80.0
  • High / Low 113 / 73.2
  • Stock P/E 246
  • Book Value 35.0
  • Dividend Yield 0.00 %
  • ROCE 9.48 %
  • ROE 9.44 %
  • Face Value 10.0

Pros

Cons

  • Though the company is reporting repeated profits, it is not paying out dividend
  • Company has low interest coverage ratio.
  • Company has a low return on equity of 12.6% over last 3 years.
  • Earnings include an other income of Rs.2.68 Cr.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024
28.44 20.46 14.98 16.93 21.96 34.22 42.24 41.95 40.68 28.44 41.40 33.29 40.32
22.74 17.63 15.36 15.27 19.42 31.18 34.62 35.66 36.67 30.51 38.51 32.08 36.53
Operating Profit 5.70 2.83 -0.38 1.66 2.54 3.04 7.62 6.29 4.01 -2.07 2.89 1.21 3.79
OPM % 20.04% 13.83% -2.54% 9.81% 11.57% 8.88% 18.04% 14.99% 9.86% -7.28% 6.98% 3.63% 9.40%
-1.79 0.49 1.04 1.30 0.64 1.93 0.26 1.87 0.16 0.98 0.52 0.16 1.02
Interest 0.11 0.41 0.21 0.31 0.45 0.58 0.70 0.60 0.44 0.58 0.68 0.65 0.62
Depreciation 1.42 1.21 1.40 1.29 1.12 1.40 1.53 1.21 1.24 1.27 1.27 1.44 1.58
Profit before tax 2.38 1.70 -0.95 1.36 1.61 2.99 5.65 6.35 2.49 -2.94 1.46 -0.72 2.61
Tax % 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 4.96% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
2.38 1.70 -0.95 1.36 1.61 3.00 5.37 6.35 2.48 -2.94 1.46 -0.72 2.62
EPS in Rs 1.01 0.72 -0.40 0.57 0.68 1.27 2.27 2.68 1.05 -1.24 0.62 -0.30 1.11
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 TTM
167 177 100 85 65 46 44 42 71 85 115 152 143
146 156 116 82 70 81 57 41 61 73 100 141 138
Operating Profit 21 21 -16 3 -5 -35 -13 1 10 12 16 11 6
OPM % 13% 12% -16% 3% -8% -77% -30% 3% 14% 14% 14% 7% 4%
3 1 40 1 1 31 0 -23 1 -0 3 4 3
Interest 11 12 12 12 11 7 2 0 1 1 2 2 3
Depreciation 8 8 5 4 4 4 3 3 4 5 5 5 6
Profit before tax 5 2 6 -13 -19 -14 -18 -25 6 5 12 7 0
Tax % 25% 40% -0% -3% -4% 15% 8% 0% 0% 0% 2% 0%
4 1 6 -12 -18 -16 -20 -25 6 5 11 7 0
EPS in Rs 2.08 0.72 3.28 -6.53 -9.90 -6.95 -8.34 -106.53 2.46 2.21 4.79 3.11 0.19
Dividend Payout % 29% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0%
Compounded Sales Growth
10 Years: -1%
5 Years: 28%
3 Years: 29%
TTM: -10%
Compounded Profit Growth
10 Years: 18%
5 Years: 19%
3 Years: 8%
TTM: -96%
Stock Price CAGR
10 Years: 9%
5 Years: %
3 Years: -14%
1 Year: -9%
Return on Equity
10 Years: -17%
5 Years: 10%
3 Years: 13%
Last Year: 9%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Sep 2024
Equity Capital 19 19 19 19 19 24 24 2 24 24 24 24 24
Reserves 49 50 53 41 22 17 -3 49 33 38 50 57 59
91 99 64 80 82 47 46 3 15 11 23 24 19
84 54 50 45 44 40 54 17 14 17 33 42 33
Total Liabilities 243 223 185 185 167 128 121 71 86 90 130 148 134
66 63 49 47 43 40 37 35 36 39 40 40 56
CWIP 0 0 0 0 0 0 0 0 1 0 2 12 2
Investments 1 1 18 18 18 1 1 0 0 0 0 0 0
175 158 118 120 106 86 82 36 50 51 88 95 77
Total Assets 243 223 185 185 167 128 121 71 86 90 130 148 134

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
35 1 9 -3 14 -7 -1 -34 -14 10 5 9
-6 -5 56 -1 -8 38 4 33 -5 -7 -7 -15
-11 -14 -66 4 -5 -31 -2 7 12 -5 10 -1
Net Cash Flow 18 -18 -0 0 -0 0 0 6 -7 -2 8 -6

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Debtor Days 187 192 303 291 302 195 208 52 49 63 130 109
Inventory Days 63 78 66 92 118 102 122 208 154 185 129 125
Days Payable 215 116 149 169 164 265 517 229 107 113 165 149
Cash Conversion Cycle 35 155 220 214 255 31 -188 31 96 135 94 84
Working Capital Days 150 204 250 320 207 79 -16 89 172 148 150 126
ROCE % 9% 9% -13% -0% -6% -36% -21% -3% 10% 11% 16% 9%

Shareholding Pattern

Numbers in percentages

Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024
90.42% 90.42% 90.12% 90.00% 90.01% 89.99% 89.99% 88.73% 88.42% 88.29% 88.29% 88.29%
9.58% 9.58% 9.88% 10.00% 9.98% 10.00% 10.00% 11.27% 11.57% 11.70% 11.71% 11.70%
No. of Shareholders 7,9107,3267,2237,2757,1997,1206,9927,3547,3677,5397,3917,295

Documents